| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$8.0M | ROE | −109.69% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $13.5M | Trading Days | 945 |
| 52W High | 3.20 |
| 52W Low | 0.00 |
| % Off High | −89.69% |
| YTD | −67.33% | 1Y | −89.49% |
| 3Y | −84.96% | Since incept. (ann.) | −41.51% |
| Ann. Volatility (1Y) | 33032.70% | Ann. Volatility (3Y) | 19058.50% |
| Sharpe (1Y) | 1.00 | Sharpe (3Y) | 0.58 |
| Max Drawdown (1Y) | −99.97% | Max Drawdown (3Y) | −99.97% |
| Beta (3Y, vs SPY) | −2.66 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LEXX | Lexaria Bioscience Corp. | $13.4M | — |
| CTXR | Citius Pharmaceuticals, Inc. | $13.7M | — |
| HIND | Vyome Holdings, Inc | $14.0M | — |
| TPST | Tempest Therapeutics, Inc. | $12.9M | — |
| COCP | Cocrystal Pharma, Inc. | $12.9M | — |
| BFRI | Biofrontera Inc. | $14.2M | — |
| KTTA | Pasithea Therapeutics Corp. | $15.0M | — |
| CYCN | Cyclerion Therapeutics, Inc. | $15.2M | — |
| SCNX | Scienture Holdings, Inc. | $15.2M | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.7M | — |
| MBRX | Moleculin Biotech, Inc. |
| $11.7M |
| — |
| MBIO | MUSTANG BIO, INC. | $15.8M | — |
